Summary
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) destroys nigrostriatal dopaminergic pathways and thereby produces a syndrome similar to Parkinson's disease. MPTP is oxidized by monoamine oxidase B (MAO B) to the 1-methyl-4-phenylpyridinium ion (MPP+), which is taken up in dopaminergic neurons through the dopamine (DA) uptake system, where it develops its toxic effect. Our observations show a new aspect of the MPP+ mode of action, in which deprenyl in mice has a partially protective effect against MPP+. Furthermore budipine, a therapeutic agent for Parkinsonism, is also able to partially prevent MPP+ toxicity. A MAO B-inhibitory component of budipine, as shown in receptor binding studies previously, could contribute to this effect. Comparable experiments with nomifensine do not exclude the possibility of budipine as an effect as a DA uptake inhibitor. An unexplained after effect of budipine leads to a large increase in 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) levels five weeks after the last administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Burns RS, Chiueh CC, Markey SP, Ebert MH, Jakobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80: 4546–4550
Cavalla D, Hadjiconstantinou M, Laird HE, Neff NH (1985) Intracerebroventricular administration of MPTP and its metabolite MPP+ decrease dopamine and increase acetylcholine in the mouse neostriatum. Neuropharmacology 24: 585–586
Chiba K, Trevor A, Castagnoli N (1983) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monamine oxidase. Biochem Biophys Res Commun 120: 574–578
Duvoisin RC, Heikkila RE, Nicklas WJ, Hess A (1986) Dopaminergic neurotoxicity of MPTP in the mouse: a murine model of parkinsonism. In: Fahn S, Marsden CD, Jenner P, Teychenne P (eds) Recent developments in Parkinson's disease. Raven Press, New York, pp 147–163
Emmert B, Varenkamp O (1923) Über chinhydronartige Verbindungen der N,N′-Dialkyl-(dihydro-gamma, gamma′-dipyridylde). Ber Dtsch Chem Ges 56: 491–501
Fuller RW, Hemrich-Luecke SK (1984) Deprenyl protection against striatal dopamine depletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Res Commun Subst Abuse 5: 241–245
Fuller RW, Hemrick-Luecke SK (1985) Mechanisms of MPTP neurotoxicity to striatal dopamine neurons in mice. Prog Neuropsychopharmacol Biol Psychiatry 9: 687–690
Fuller RW, Hemrick-Luecke SK (1986) Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Pharmacol Exp Ther 232: 696–701
Gupta M, Felten DL, Gash DM (1984) MPTP alters central catecholamine neurons in addition to the nigrostriatal system. Brain Res Bull 13: 737–742
Hadjiconstantinou M, Xu J, Cavalla D, Laird HE, Neff NH (1986) The neurotoxicity of MPTP may have a cholinergic component. In: Markey SP, Castagnoli N Jr, Trevor AJ, Kopin IJ (eds) MPTP: a neurotoxin producing a parkinsonian syndrom. Academic Press, London, pp 481–485
Hallmann H, Olson L, Jonnson G (1984) Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. Eur J Pharmacol 97: 133–136
Hallmann H, Lange I, Olson L (1985) Neurochemical and histochemical effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. J Neurochem 44: 118–127
Hefti F, Enz A, Melamed E (1985) Partial lesions of the nigrostriatal pathway in the rat. Neuropharmacology 24: 19–23
Heikkila RE, Cabbat FS, Manzino L, Duvoisin RC (1984a) Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on neostriatal dopamine in mice. J Neuropharmacol 23: 711–713
Heikkila RE, Hess A, Duvoisin RC (1984b) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science 224: 1451–1453
Heikkila RE, Duvoisin RC, Finberg JPM, Youdim MBH (1985a) Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-35, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol 116: 313–317
Heikkila RE, Youngster SK, Mancino L, Cabbat FS, Duvoisin RC (1985b) Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and related compounds on the uptake of (3H)3,4-dihydroxyphenylethylamine and (3H)5-hydroxytryptamine in neostriatal synapsomal preparations. J Neurochem 44: 310–313
Heikkila RE, Hess A, Duvoisin RC (1985c) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse: relationship between monoaminoxidase, MPTP metabolism and neurotoxicity. Life Sci 36: 231–236
Heikkila RE, Nicklas WJ, Vyas I, Duvoisin R (1985d) Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Neurosci Lett 62: 389–394
Langsten IW, Ballard P, Tetrud IW, Irwin I (1983) Chronic parkinsonism in humans due to the product of meperidin analog synthesis. Science 219: 979–984
Langstom IW, Irwin I, Langston EB, Forno LS (1984) The importance of the “4–5” double bond for neurotoxicity in primates of the pyridine derivative MPTP. Neurosci Lett 50: 289–294
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193: 265–275
Markey P, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA (1984) Interneuronal generation of a pyridinium metabolite may cause a drug-induced parkinsonism. Nature 311: 464–467
Mayer RA, Jarvis MF, Wagner GC (1985) Cocaine blocks the dopamine depletion, induced by MPTP. Res Commun Chem Pathol Pharmacol 49: 145–148
Melamed E, Rosenthal J, Cohen O, Globus M, Uzzan A (1985) Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP. Eur J Pharmacol 116: 179–181
Melamed E, Youdim MBH (1985) Prevention of dopaminergic toxicity of MPTP in mice by phenylethylamine, a specific substrate of type B monoamine oxidase. Br J Pharmacol 86: 529–531
Menge HG, Brand U (1982) Zusammenfassende Darstellung der Pharmacologie von Budipin, einem neuen 4,4-Diphenylpiperidinderivat für die Parkinsontherapie. Arzneimittelforschung 32: 85–97
Mytilineou C, Cohen G (1985) Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J Neurochem 45: 1951–1953
Neuser D, Stasch JP, Witteler M, Kuhn W, Gerlach M, Jutzi P, Przuntek H (1983) The interaction of 1-alkyl-4, 4-diphenylpiperidine with opiate rezeptors. Eur J Pharmacol 87: 315–318
Przuntek H, Stasch JP (1985) Biochemical and pharmacological aspects of the mechanism of action of budipine. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 101–112
Przuntek H, Ruß H, Henning K, Pindur U (1984) The protective effect of 1-tert.butyl-4,4-diphenylpiperidine against the nigrostriatal neurodegeneration caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 37: 1195–1200
Ricaurte GA, Langston JW, DeLanney LE, Irwin I, Brooks JP (1985) Dopamine uptake blockers protect against the dopamin depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci Lett 59: 265–270
Russ H, Stasch JP, Witteler M, Neuser D, Przuntek H (1983) Der Effekt von Budipin auf das Parkinsonsyndrom. Versuch einer neuropharmacologischen Erklärung. In: Seitz D, Vogel P (eds) Verhandlungen der Deutschen Gesellschaft für Neurologie, Band 2. Springer, Wien New York, pp 757–760
Russ H, Pindur U, Przuntek H (1986) The interaction of 1-alkyl-4,4-diphenylpiperidines with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine receptor binding site. J Neural Transm 65: 157–166
Singer P, Salach JI, Crabtree D (1985) Reversible inhibition and mechanism based irreversible inactivation of monoamine oxidase by 1-methyl.4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Biophys Res Commun 127: 707–712
Snyder AM, Zigmoud M, Lund RD (1986) Sprouting of serotoninergic afferents into striatum after dopamin-depleting lesions in infant rats: a retrograde transport and immunocytochemical study. J Comp Neurol 245: 274–281
Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol Scand [Suppl] 367: 69–75
Vetulani J, Reichenberg K, Wiszniowska G (1972) Asymmetric behavioral and biochemical effects of unilateral injections of 6-hydroxydopamine into the lateral brain ventricle of the rat. Eur J Pharmacol 19: 231–238
Wagner J, Vitali P, Palfreyman MG, Zraika M, Huot S (1982) Simultaneous determination of 3,4-dihydroxy-phenylalanin, 5-hydroxytryptophan, dopamine, 4-hydroxy-3-meth-oxyphenylalanin, norepinephrin, 3,4-dihydroxy-phenylacetic acid, homovanillic acid, serotonin, and 5-hydroxyindolacetic acid in rat cerebrospinal fluid and brain by high performance liquid chromatography with electrochemical detection. J Neurochem 38: 1241–1254
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mihatsch, W., Russ, H. & Przuntek, H. Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: Effects of simultaneously administered nomifensine, deprenyl, and 1-t-butyl-4,4-diphenylpiperidine. J. Neural Transmission 71, 177–188 (1988). https://doi.org/10.1007/BF01245711
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01245711